Evidence map›Paper›PMID 41357868›Full record

ArticleFrontiers in pharmacology2025

Correction: Methodological study protocol for the European Atlas of clinical trials in cancer and haematology.

Mercè Cases, Rachel Giles, Tamás Ágh, Maria Piggin, Jan Geissler, Monica Racovita, Judit Hagymásy, Lora Ruth Wogu, Ákos Józwiak, Albina Hyseni-Bocolli and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Mercè CasesEuropean Patient Advocacy Institute, Riemerling, Germany.
Rachel GilesVHL Europa, Vlaardingen, Netherlands.
Tamás ÁghSyreon Research Institute, Budapest, Hungary.
Maria PigginPNH Global Alliance, Tiel, Netherlands.
Jan GeisslerEuropean Patient Advocacy Institute, Riemerling, Germany.
Monica RacovitaMyeloma Patients Europe, Brussels, Belgium.
Judit HagymásySyreon Research Institute, Budapest, Hungary.
Lora Ruth WoguEuropean Sickle Cell Federation-ESCF, Dublin, Ireland.
Ákos JózwiakSyreon Research Institute, Budapest, Hungary.
Albina Hyseni-BocolliChildhood Cancer International - Europe, Vienna, Austria.
Dalma Hosszú *Syreon Research Institute, Budapest, Hungary.
Ananda Plate *European Patient Advocacy Institute, Riemerling, Germany.
EuroACT Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2025.1558556.].

Indexed as

cancerclinical trialshaematologypatientpatient reported outcomerare disease

Identifiers

PMID41357868
PMCPMC12679273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.